• 1
    Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996; 52: 273280.
  • 2
    Afzal Mir M, Kafetzakis EM. Assessment of perhexiline maleate in angiographically proven intractable angina: a double-blind trial. Am Heart J 1978; 96: 350354.
  • 3
    White H, Lowe J. Antianginal efficacy of perhexiline maleate in patients refractory to beta-adrenoreceptor blockade. Int J Cardiol 1983; 3: 145455.
  • 4
    Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JDF. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 1982; 284: 295299.
  • 5
    Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984; 25: 10571064.
  • 6
    Singlas E, Goujet MA, Simon P. Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur J Clin Pharmacol 1978; 14: 195201.
  • 7
    Horowitz JD, Sia STB, Macdonald PS, Goble AJ, Louis WJ. Perhexiline maleate treatment for severe angina pectoris – correlations with pharmacokinetics. Int J Cardiol 1986; 13: 219229.
  • 8
    Pilcher J, Cooper JDH, Turnell DC, Matenga J, Paul R, Lockhart JDF. Investigations of long-term treatment with perhexiline maleate using therapeutic monitoring and electromyography. Ther Drug Monit 1985; 7: 5460.
  • 9
    Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81: 12601270.
  • 10
    Morris RG, Sallustio BC, Saccoia NC, Mangas S, Fergusson LK, Kassapidis C. Application of an improved HPLC perhexiline assay to human plasma specimens. J Liquid Chromatogr 1992; 15: 32193232.
  • 11
    Wright GJ, Zeiger AV, Leeson GA, Lang JF. The absorption, excretion and metabolism of perhexiline maleate by the human. Postgrad Med J 1973; 49: 815.
  • 12
    Amoah AGB, Gould BJ, Parke DV, Lockhart JDF. Further studies on the pharmacokinetics of perhexiline maleate in humans. Xenobiotica 1986; 16: 6368.
  • 13
    Cooper RG, Evans DAP, Whibley EJ. Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet 1984; 21: 2733.
  • 14
    Cooper RG, Evans DAP, Price AH. Studies on the metabolism of perhexiline in man. Eur J Clin Pharmacol 1987; 32: 569576.
  • 15
    Horowitz JD, Morris PM, Drummer OH, Goble AJ, Louis WJ. High-performance liquid chromatographic assay of perhexiline maleate in plasma. J Pharm Sci 1981; 70: 320322.
  • 16
    Cooper JDH, Turnell DC, Pilcher J, Lockhart D. Therapeutic monitoring of the anti-anginal drug perhexiline maleate. Ann Clin Biochem 1985; 22: 614617.
  • 17
    Cooper RG, Harper G, Price AH, Evans DAP, Lockhart D. Simultaneous determination of perhexiline and its monohydroxy metabolites in biological fluids by gas chromatography – electron capture detection. J Chromatogr 1986; 381: 305314.
  • 18
    Amoah AGB, Gould BJ, Parke DV. Single-dose pharmacokinetics of perhexiline administered orally to humans. J Chromatogr 1984; 305: 401409.
  • 19
    Kerry NL, Somogyi AA, Bochner F, Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol 1994; 38: 243248.
  • 20
    Guttendorf RJ, Wedlund PJ. Genetic aspects of drug disposition and therapeutics. J Clin Pharmacol 1992; 32: 107117.
  • 21
    Ingelman-Sundberg M. Duplication, multiplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. Drug Metab Rev 1999; 31: 449459.
  • 22
    Lovile R, Daly AK, Matre GE, Molven A, Steen VM. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype. A role for the CYP2D6*35 allele in ultrarapid metabolism. Pharmacogenetics 2001; 11: 4555.
  • 23
    Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516520.
  • 24
    Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278: 441446.
  • 25
    Hussein R, Charles BG, Morris RG, Rasiah RL. Population pharmacokinetics of perhexiline from routine monitoring data. Ther Drug Monit 2001; 23: 636643.
  • 26
    Ereshefsky L, Riesenman C, Lam YWF. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 1995; 29(Suppl 1): 1019.
  • 27
    Alfaro CL, Lam YWF, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000; 40: 5866.
  • 28
    Alderman CP, Hundertmark JD, Soetrama TW. Interaction of serotonin re-uptake inhibitors with perhexiline. Aust NZ J Psych 1997; 31: 601603.